Company Overview of Celyad SA
Celyad SA, a biopharmaceutical company, focuses on engineered cell therapy treatments. It operates in two segments, Cardiology and Immuno-oncology. The company’s lead product candidate in cardiovascular disease is C-Cure, an autologous cell therapy for the treatment of patients with ischemic heart failure. Its lead product candidate in oncology disease is CAR-T NKR-2, an autologous chimeric antigen receptor (CAR) for the treatment of cancer. In addition, the company’s preclinical stage product candidates include NKp30, an activated receptor of NK cells; B7H6 therapies, which kills cancer cells; and CAR T-cell, an allogeneic T-cell platform. Further, it offers C-CATHez, a cell injection cathe...
Rue Edouard Belin 2
Founded in 2004
Key Executives for Celyad SA
CEO & Executive Director
Total Annual Compensation: €562.0K
Compensation as of Fiscal Year 2016.
Celyad SA Key Developments
Celyad SA - Special Call
Feb 13 18
To consider the topic of CYAD-01 (CAR-T NKG2D) cell therapy for the treatment of blood cancers
Celyad Reports Clinical and Operational Developments for the Third Quarter Ended September 30, 2017
Nov 22 17
Celyad reported clinical and operational developments for the third quarter ended September 30, 2017. In July 2017, Celyad initiated the SHRINK trial, an open-label Phase 1 study evaluating the safety and clinical activity of multiple doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer. The trial includes a dose escalation and an extension stage. The dose escalation design will include three dose levels adjusted to body weight: up to 1x108, 3x108 and 1x109 CYAD-01 cells. At each dose, patients will receive three successive administrations, two weeks apart, at the specified dose. The dose escalation portion of the study will enroll up to 18 patients and the extension phase will enroll 21 additional patients. SHRINK is being conducted in oncology centers in Belgium. In August 2017, Celyad amended its existing agreements with Celdara Medical LLC and Dartmouth College. Under the amended agreements, Celyad will receive an increased share of future revenues generated by these assets, including revenues from its sublicensees. In return, Celyad paid Celdara Medical and Dartmouth College an upfront payment of $12.5 million (€10.6 million) and $12.5 million worth of Celyad shares at a share price of €32.35 corresponding to a 14% premium versus the prior trading day.
Celyad SA Presents at PiperJaffray 29th Annual Healthcare Conference, Nov-28-2017 04:30 PM
Nov 21 17
Celyad SA Presents at PiperJaffray 29th Annual Healthcare Conference, Nov-28-2017 04:30 PM. Venue: Lotte New York Palace Hotel, Track 5, Hubbard 1, 5th Floor, New York, New York, United States. Speakers: David Edward Gilham, Vice President of Research & Development, Patrick Jeanmart, CFO & Principal Accounting Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 3, 2017